| Income Statement | 2025-09-30 | 2025-03-31 | 2024-12-31 | |
|---|---|---|---|---|
| Revenue | - | 15,000,000 | 662,715 | |
| Research and development | 3,785,649 | 1,616,011 | 1,737,039 | |
| General and administrative | 1,867,040 | 1,406,796 | 2,629,187 | |
| Total operating expenses | 5,652,689 | 3,022,807 | 4,366,226 | |
| Research and development incentive award | - | 5,227 | -306,233 | |
| Loss from operations | -5,652,689 | 11,977,193 | -3,703,511 | |
| Interest income, net | 141,996 | 12,741 | 30,615 | |
| Loss on foreign currency translation | -61,735 | 172,946 | 629,501 | |
| (loss) gain on fair value adjustments | -4,368,869 | -976,678 | 805,422 | |
| Total other (loss) income | -4,288,608 | -796,218 | 1,771,771 | |
| Income (loss) before income tax expense | -9,941,297 | 11,180,975 | -1,931,740 | |
| Income tax benefit | -34,793 | -81,186 | 11,609 | |
| Net loss | -9,906,504 | 11,262,161 | -1,943,349 | |
| Unrealized gain on foreign currency translation | 49,221 | -195,818 | -1,288,433 | |
| Total other comprehensive income | 49,221 | -195,818 | -1,288,433 | |
| Total comprehensive loss | -9,857,283 | 11,066,343 | -3,231,782 | |
| Earnings per share, basic, total | -4.41 | 6.55 | -1.23 | |
| Net income per share - diluted | -4.41 | 6.55 | -1.23 | |
| Weighted average shares - basic | 2,246,066 | 1,719,073 | 1,575,244 | |
| Weighted average shares - diluted | 2,246,066 | 1,719,073 | 1,575,244 | |
Neuphoria Therapeutics Inc. (NEUP)
Neuphoria Therapeutics Inc. (NEUP)